Acumen Pharmaceuticals, Inc.
ABOSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. At a $161.1M market cap, Acumen Pharmaceuticals, Inc. ranks as a micro-cap company within healthcare. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Market Cap
$161.1M
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
-1.48
EPS (TTM)
$-1.85
EPS (Fwd)
$-1.51
ROE
-93.2%
ROA
-42.4%
Cash
$128.4M
Total Debt
$31.2M
Free CF
-$67.4M
52W Change
33.5%
Annual Financials
Cash vs Debt
Where ABOS stands vs its 150-day and 200-day moving averages
As of the June 30, 2026 close, ABOS finished 14.94% above its 150-day moving average ($2.41) and 22.57% above its 200-day moving average ($2.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABOS overbought or oversold?
At the June 30, 2026 close, ABOS's RSI(14) was 74.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $128.4M in cash comfortably exceeding the $31.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$67.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -93.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.34 suggests ABOS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Acumen Pharmaceuticals, Inc.'s trajectory.